An important focus of Angelini research is the identification of new painkilling compounds. It is studying an innovative combination of two known drugs that appear to have synergic effects and is working with the Pharmacy Department of Genoa University to understand the molecular mechanisms involved. The research is evaluating possible cross-talk of specific receptors on spinal neurons and seeking to identify the neurotransmitter pathway that mediated the painkilling effects. The outcome should identify the types of pain that would respond best to this treatment.
A university research group has been studying the proteins involved in bacterial resistance for ten years. Angelini has collaborated with the group on computational studies of molecule-target interactions, particularly on the phenomenon of efflux systems, where bacteria defeat antibiotics by expelling them. The aim is to modify these antibiotics to prevent their being recognised by bacteria.
Angelini will host two PhD students from the University of Naples Federico II and the University of Salento for their industrial-oriented training as part of the innovative PhD course funded by MIUR (the Italian Ministry of Education, University and Research). The PhD courses, co-sponsored by European Social Fund, aim to strengthen the industrial links of Italian doctorate courses.
Angelini is an associated partner of “The European Master in Translational Cosmetic and Dermatological Sciences” (EMOTION), a two-year Master’s funded by the European Commission (www.emotion-master.eu/). EMOTION aims to educate future scientists and professionals in dermocosmetics and dermatologic therapies, and equip them to work in R&D.
The cooperation between Angelini and the Italian Institute of Technology focuses on new CNS drugs. Validation of innovative CNS biological targets has led to the study of new therapies for rare illnesses such as Fragile X syndrome. Angelini has designed and synthesised innovative molecules and the project is now in the lead optimisation phase, taking advance of IIT’s advanced pharmacological experimentation technologies. These studies could lead to the identification of molecules for use in other CNS conditions such as mood disorders.
Angelini and IIT are also seeking to identify for the first time how the complex link between a molecule and its target is formed.
Angelini is working with King’s College to verify the analgesic efficacy of an innovative combination of two existing drugs in advanced models that integrate behavioural and molecular aspects. This approach will provide international validation for the results of Angelini’s research and also give it access to innovative scientific research and results that could prove useful for new projects in Angelini’s key areas of interest.
Angelini is cooperating with the leading psychiatric centers in Italy in a phase IV study of the tolerability and efficacy of a new prolonged-release formulaton of lithium sulphate, in bipolar patients who are poorly tolerant to immediate-release lithium treatment.
Angelini closely cooperates with leading research networks and working groups in the field of CNS disorders to develop and deliver innovative methodologies and treatments. These networks include ECNP and the ECNP child and adolescent psychiatry.
Angelini cooperates with the CVBF Consortium on the clinical development of Trazodone for treating insomnia in children and adolescents with neurodevelopmental disorders. The Paediatric Investigation Plan (PIP) was approved by the EMA and should offer the possibility of meeting a very important but currently unsatisfied medical need.
We are looking for innovative solutions in healthcare from the early development phase.
If you have an idea or a new project starting from the early development phase and you desire to discuss for potential partnership opportunities, or if you are looking for a partner to accomplish specific development steps, please contact email@example.com